Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.58 |
| ▸ | KIT | P10721 | 6/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15506892 | 0.79 | AURKA (0.48) | FLT3KITPTK2CHEK1AURKA | |
| SCHEMBL578690 | 0.79 | GSK3A (0.56) | FLT3KITPTK2CHEK1AURKA | |
| SCHEMBL4393743 | 0.79 | GSK3A (0.53) | FLT3KITPTK2AURKAGSK3A | |
| SCHEMBL579089 | 0.79 | GSK3B (0.70) | PTK2AURKAGSK3AGSK3B | |
| SCHEMBL11987614 | 0.78 | PTK2 (0.54) | FLT3PTK2CHEK1AURKAGSK3A | |
| SCHEMBL1627996 | 0.78 | PTK2 (0.70) | FLT3KITPTK2 | |
| SCHEMBL5562631 | 0.78 | AURKA (0.52) | FLT3KITPTK2AURKAGSK3A | |
| SCHEMBL15506646 | 0.78 | FLT4 (0.51) | FLT3KITPTK2AURKAFLT4 | |
| SCHEMBL1916423 | 0.78 | JAK3 (0.65) | FLT3KITPTK2CHEK1AURKA | |
| SCHEMBL1917337 | 0.77 | STK17A (0.60) | PTK2AURKAGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | GOT1, AADAT, ADH1A | FLT3 1292/4885KIT 3706/4885PTK2 3451/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT3 55/4885KIT 28/4885PTK2 240/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT3 33/4885KIT 18/4885PTK2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.